InsiderClue
← All stocks

Relay Therapeutics, Inc.

RLAY Net selling
CIK 0001812364 #1471 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$129.02M
$5.86M on a plan · $4.79M straight out of an exercise
Sold at will
$118.37M
19 of 38 sales
Net
−$129.02M
−$118.37M against sales at will

By person

6 insiders · 38 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
SVF Pauling (Cayman) Ltd entity
10% owner
—
$116.40M (1)
−$116.40M
21,904,963
10.00%
$414.88M
−21.5%
Catinazzo Thomas
Chief Financial Officer
—
$5.18M (16) scheduled
−$5.18M
122,851
0.0561%
$2.33M
−54.6%
Patel Sanjiv
President and CEO
—
$3.61M (5) scheduled
−$3.61M
1,605,951
0.7328%
$30.42M
−31.0%
Bergstrom Donald A
President, R&D
—
$2.36M (8) scheduled
−$2.36M
399,130
0.1821%
$7.56M
−10.1%
Rahmer Peter
See remarks
—
$1.47M (8) scheduled
−$1.47M
223,657
0.1021%
$4.24M
−34.8%
Adams Brian
Chief Legal Officer
—
—
—
371,472
0.1695%
$7.04M
+14.7%

Individual transactions

6
Insider
Date
Role
Action
Shares
Price
Amount
Bergstrom Donald A
22 Jun 2026
President, R&D
Sold after exercise
93,456
$16.94
$1.58M
Catinazzo Thomas
22 Jun 2026
Chief Financial Officer
Sold after exercise
51,560
$16.97
$874.97K
Catinazzo Thomas
22 Jun 2026
Chief Financial Officer
Sold after exercise
61,563
$16.97
$1.04M
Catinazzo Thomas
22 Jun 2026
Chief Financial Officer
Sold after exercise
56,323
$16.97
$955.80K
Catinazzo Thomas
22 Jun 2026
Chief Financial Officer
Sold after exercise
17,717
$17.01
$301.37K
Catinazzo Thomas
9 Apr 2026
Chief Financial Officer
Sold after exercise
1,800
$15.00
$27.00K
Show all 38 transactions →

What was left out

Form 4 filings counted 43
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 1
Sales on a Rule 10b5-1 plan 13
Sales straight out of an exercise 6
Sales at will 19
Transactions with no price 0
Shares from compensation/vesting 272,802
History held since 20 Jul 2020